Downregulation of APP pathway components is a well-known mechanism of tumor immune escape that can contribute to tumor progression and lead to resistance to cancer immunotherapy, including blockade of PD-1/PD-L1 signaling [46]. The gene discussed is APP; the disease is neoplasm.